Internet-based cognitive assessment tool: Sensitivity and validity of a new online cognition screening tool for patients with bipolar disorder

Miskowiak, Kamilla Woznica; Jespersen, Andreas E.; Obenhausen, Kia; Hafiz, Pegah; Hestbæk, Emilie; Gulyas, Lorant; Kessing, Lars Vedel; Bardram, Jakob E.

doi:10.1016/j.jad.2021.04.039

Cited by 9 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, researchers have begun to explore the potential of cognitive markers to inform clinical decision-making in the treatment of depression [94] and as a specific treatment target [95]. We include an extensive neurocognitive battery at inclusion and hope to extend the follow-up assessments to include a brief internetbased self-administered cognitive assessment [96] to follow long-term cognitive function.…”

Section: Discussionmentioning

confidence: 99%

Deep phenotyping towards precision psychiatry of first-episode depression — the Brain Drugs-Depression cohort

et al. 2023

View full text Add to dashboard Cite

Background Major Depressive Disorder (MDD) is a heterogenous brain disorder, with potentially multiple psychosocial and biological disease mechanisms. This is also a plausible explanation for why patients do not respond equally well to treatment with first- or second-line antidepressants, i.e., one-third to one-half of patients do not remit in response to first- or second-line treatment. To map MDD heterogeneity and markers of treatment response to enable a precision medicine approach, we will acquire several possible predictive markers across several domains, e.g., psychosocial, biochemical, and neuroimaging. Methods All patients are examined before receiving a standardised treatment package for adults aged 18–65 with first-episode depression in six public outpatient clinics in the Capital Region of Denmark. From this population, we will recruit a cohort of 800 patients for whom we will acquire clinical, cognitive, psychometric, and biological data. A subgroup (subcohort I, n = 600) will additionally provide neuroimaging data, i.e., Magnetic Resonance Imaging, and Electroencephalogram, and a subgroup of patients from subcohort I unmedicated at inclusion (subcohort II, n = 60) will also undergo a brain Positron Emission Tomography with the [11C]-UCB-J tracer binding to the presynaptic glycoprotein-SV2A. Subcohort allocation is based on eligibility and willingness to participate. The treatment package typically lasts six months. Depression severity is assessed with the Quick Inventory of Depressive Symptomatology (QIDS) at baseline, and 6, 12 and 18 months after treatment initiation. The primary outcome is remission (QIDS ≤ 5) and clinical improvement (≥ 50% reduction in QIDS) after 6 months. Secondary endpoints include remission at 12 and 18 months and %-change in QIDS, 10-item Symptom Checklist, 5-item WHO Well-Being Index, and modified Disability Scale from baseline through follow-up. We also assess psychotherapy and medication side-effects. We will use machine learning to determine a combination of characteristics that best predict treatment outcomes and statistical models to investigate the association between individual measures and clinical outcomes. We will assess associations between patient characteristics, treatment choices, and clinical outcomes using path analysis, enabling us to estimate the effect of treatment choices and timing on the clinical outcome. Discussion The BrainDrugs-Depression study is a real-world deep-phenotyping clinical cohort study of first-episode MDD patients. Trial Registration Registered at clinicaltrials.gov November 15th, 2022 (NCT05616559).

show abstract

Section: Discussionmentioning

confidence: 99%

Deep phenotyping towards precision psychiatry of first-episode depression — the Brain Drugs-Depression cohort

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Verbal interaction with the experimenter [47], [63], [67], [70], [77], [82], [85], [152], [172], [192], [198], [200], [202], [216], [217], [222], [228] 17 Authomatic speech recognition [113] 1…”

Section: Verbalmentioning

confidence: 99%

Visualization and Interaction Technologies in Serious and Exergames for Cognitive Assessment and Training: A Survey on Available Solutions and Their Validation

2022

View full text Add to dashboard Cite

show abstract

“…), it is crucial to have a reliable, remote battery to assess cognitive functioning in individuals with severe mental illness. To our knowledge, no remote version of the MCCB has currently been developed, but web-based and smartphone app assessments designed to mirror widely used assessments like the MCCB show strong correlations with in-person measures in schizophrenia spectrum, bipolar, and healthy control populations ( Biagianti et al, 2019 ; Domen et al, 2019 ; Miskowiak et al, 2021 ). Though they still require validation for at-home administration, these assessments appear to be comparable, albeit not identical, alternatives to traditional assessment.…”

Section: Introductionmentioning

confidence: 99%

Validity of remote administration of the MATRICS Consensus Cognitive Battery for individuals with severe mental illness

Russell

Funsch

Springfield

et al. 2022

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

The MATRICS Consensus Cognitive Battery (MCCB) is a gold-standard tool for assessing cognitive functioning in individuals with severe mental illness. This study is an initial examination of the validity of remote administration of 4 MCCB tests measuring processing speed (Trail Making Test: Part A, Animal Fluency), working memory (Letter-Number Span), and verbal learning and memory (Hopkins Verbal Learning Test-Revised). We conducted analyses on individuals with bipolar disorder (BD) and schizophrenia-spectrum disorders (SCZ), as well as healthy volunteers, who were assessed in-person (BD = 80, SCZ = 116, HV = 14) vs. remotely (BD = 93, SCZ = 43, HV = 30) to determine if there were significant differences in performance based on administration format. Additional analyses tested whether remote and in-person assessment performance was similarly correlated with symptom severity, cognitive and social cognitive performance, and functional outcomes. Individuals with BD performed significantly better than those with SCZ on all MCCB subtests across administration format. Animal Fluency did not differ by administration format, but remote participants performed significantly worse on Trail Making and HVLT-R. On the Letter-Number Span task, individuals with bipolar disorder performed significantly better when participating remotely. Finally, patterns of correlations with related constructs were largely similar between administration formats. Thus, results suggest that remote administration of some of the MCCB subtests may be a valid alternative to in-person testing, but more research is necessary to determine why some tasks were affected by administration format.

show abstract

Internet-based cognitive assessment tool: Sensitivity and validity of a new online cognition screening tool for patients with bipolar disorder

Cited by 9 publications

References 43 publications

Deep phenotyping towards precision psychiatry of first-episode depression — the Brain Drugs-Depression cohort

Deep phenotyping towards precision psychiatry of first-episode depression — the Brain Drugs-Depression cohort

Visualization and Interaction Technologies in Serious and Exergames for Cognitive Assessment and Training: A Survey on Available Solutions and Their Validation

Validity of remote administration of the MATRICS Consensus Cognitive Battery for individuals with severe mental illness

Contact Info

Product

Resources

About